Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors

SWOG Cancer Research Network

Status and phase: Enrolling; Phase 2

Conditions: Stage I Pancreatic Neuroendocrine Tumor AJCC v8; Metastatic Malignant Neoplasm in the Liver; Stage II Pancreatic Neuroendocrine Tumor AJCC v8; Stage III Pancreatic Neuroendocrine Tumor AJCC v8; Pancreatic Neuroendocrine Tumor

Treatments: Drug: Capecitabine; Drug: Temozolomide

Study type: Interventional

Funder types: NETWORK; NIH

Identifiers

NCT05040360

NCI-2021-06619 (Registry Identifier)

U10CA180888 (U.S. NIH Grant/Contract)

S2104 (Other Identifier)

Details and patient eligibility

About

This phase II trial studies the effect of capecitabine and temozolomide after surgery in treating patients with high-risk well-differentiated pancreatic neuroendocrine tumors. Chemotherapy drugs, such as capecitabine and temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving capecitabine and temozolomide after surgery could prevent or delay the return of cancer in patients with high-risk well-differentiated pancreatic neuroendocrine tumors.

Full description

PRIMARY OBJECTIVE:

I. To evaluate recurrence-free survival (RFS) in participants with resected pancreatic neuroendocrine tumors (pNETs) randomized to treatment with capecitabine + temozolomide (CAPTEM) compared to observation only.

SECONDARY OBJECTIVES:

I. To evaluate overall survival (OS) in participants randomized to treatment with CAPTEM compared to observation only.

II. To evaluate the safety and tolerability of CAPTEM compared to observation only.

BANKING OBJECTIVE:

I. To bank specimens for future correlative studies.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM I: Patients receive capecitabine orally (PO) twice daily (BID) on days 1-14 and temozolomide PO once daily (QD) on days 10-14. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

ARM II: Patients undergo surveillance with no active treatment.

After completion of study treatment, patients are followed up every 6 months for 3 years and then annually until 5 years from randomization.

Enrollment: 141 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Participants must have a histologic diagnosis of well-differentiated pancreatic neuroendocrine tumor (pNET) that was resected between 14 and 90 days prior to registration. Participants must have a scan within 90 days prior to registration without evidence of metastatic disease. Acceptable scans are multiphase computed tomography (CT) abdomen, magnetic resonance imaging (MRI) with intravenous (IV) contrast of the abdomen, or positron emission tomography (PET)-CT DOTATATE imaging if the DOTATATE PET-CT included IV iodine contrast for the CT portion of the exam

• Resection must have been an R0 or R1 per treating investigator's assessment and/or pathology report

• Ki-67 testing, which is considered part of standard of care in the pathology report, must have been performed between 14 and 90 days prior to registration and the result must be >= 3% and =< 55%. Treating investigators are encouraged to contact the S2104 Study Chairs and/or the study pathology chair with questions. If more than one Ki-67 is reported (e.g., primary tumor versus lymph node or metastatic site), the highest one should be considered for the study eligibility criteria

• Participants with localized resected pNETS must have a Zaidi score of >= 3 derived by the following factors and points:

  • 1 point; symptomatic tumor defined as one of the following:

    • Gastrointestinal bleed
    • Jaundice
    • Gastrointestinal obstruction
    • Pain from primary tumor prior to surgical resection
    • Pancreatitis

  • 2 points; primary pancreas tumor size > 2 cm

  • 1 point; Ki-67 3% to 20%

  • 1 point; lymph node positivity = 1

  • 6 points; Ki-67 21% to 55%

• Participants may have received resection/ablation of liver oligo-metastatic disease (up to 5 liver metastases) at the time of well-differentiated pNET resection

• Participants must have recovered from effects of surgery as determined by the treating investigator

• Participants must be >= 18 years old

• Participants must have Zubrod performance status of 0-2

• Participants must have a complete medical history and physical exam within 28 days prior to registration

• Leukocytes >= 3 x 10^3/uL (within 28 days prior to registration)

• Absolute neutrophil count >= 1.5 x 10^3/uL (within 28 days prior to registration)

• Platelets >= 100 x 10^3/uL (within 28 days prior to registration)

• Total bilirubin =< institutional upper limit of normal (ULN) unless history of Gilbert's disease. Participants with history of Gilbert's disease must have total bilirubin =< 5 x institutional ULN (within 28 days prior to registration)

• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =< 3 x institutional ULN (within 28 days prior to registration)

• Serum creatinine =< 1.5 x institutional ULN (within 28 days prior to registration)

• Calculated creatinine clearance >= 50 ml/min (within 28 days prior to registration)

• Participants must be able to swallow pills

• Participants must be able to tolerate CT or magnetic resonance (MR) imaging including contrast agents as required for their treatment and the protocol

• No other active malignancy or history of prior malignancy is allowed, except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the participant is currently in complete remission, or any other cancer from which the participant has been disease free for two years

• Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines

Exclusion criteria

• Participants must not have unresected or unablated metastatic disease
• Participants must not have clinically apparent central nervous system metastases or carcinomatous meningitis
• Participants must not have received prior neoadjuvant therapy for treatment of pancreatic neuroendocrine tumor. Use of somatostatin analogs prior to surgery is permitted
• Participants must not have received somatostatin analogs after surgery
• Participants must not be planning to receive warfarin while on protocol treatment. Other anticoagulants are allowed
• Participants must not have history of allergic reactions attributed to compounds of similar chemical or biologic composition to temozolomide or capecitabine
• Participants must not have known absorption issues that would limit the ability to absorb study agents
• Participants must not have had an arterial thromboembolic event, unstable angina, or myocardial infarction within 12 months prior to registration
• Participants must not have active or uncontrolled infection
• Participants must not have serious medical or psychiatric illness that could affect study participation in the judgement of the treating investigator
• Participants must not be pregnant due to the possibility of harm to the fetus. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

141 participants in 2 patient groups

Arm I (capecitabine, temozolomide)

Experimental group

Description:

Patients receive capecitabine PO BID on days 1-14 and temozolomide PO once QD on days 10-14. Treatment repeats every 28 days for up to 4 cycles in the absence of disease progression or unacceptable toxicity.

Treatment:

Drug: Temozolomide

Drug: Capecitabine

Arm II (surveillance)

No Intervention group

Description:

Patients undergo surveillance with no active treatment.